AZN climbs more than 2% after CSPC deal and fresh EU drug approval

Traders Union
All News
Financial News
Astrazeneca surges 2.31% today to GBX14374

Highlights

AstraZeneca agreed to co-develop renal disease therapies with CSPC Pharmaceutical Group in a deal valued up to $1.77 billion.
The European Commission approved Enhertu, strengthening AstraZeneca's portfolio in HER2-positive metastatic solid tumor treatments.
AstraZeneca trades in an overbought zone near resistance at GBX14,686, with a five-day expected range of GBX13,950 to GBX14,798 amid mixed short-term momentum signals.

Drug pipeline expansion highlighted by CSPC partnership and EU approval

AstraZeneca recently entered into a partnership with CSPC Pharmaceutical Group in a deal valued at up to $1.77 billion to co-develop renal disease treatments. The company also received European Commission approval for Enhertu in treating HER2-positive metastatic solid tumors. These developments highlight AstraZeneca’s ongoing focus on expanding its drug pipeline and strengthening its global portfolio.

Anton Kharitonov, expert at Traders Union, notes the technical setup appears overextended after AstraZeneca’s sharp intraday rally. He sees conflicting short-term signals, with positive momentum offset by strong sell cues from oscillators. Kharitonov points out that the move follows upbeat news on partnerships and product approvals, yet warns market sentiment may have become too optimistic. He believes that current price action is vulnerable to reversals given the overbought readings. "Despite the news-driven spike, I remain cautious — a pullback below GBX14,312 cannot be ruled out if momentum falters."

Viktoras Karapetjanc, expert at Traders Union, highlights AstraZeneca’s robust fundamentals following its CSPC partnership and fresh regulatory win for Enhertu. He believes these developments reinforce AstraZeneca's leadership in R&D and global pipeline expansion. Karapetjanc sees the alignment above all key moving averages as confirming underlying market strength. The analyst views the bullish structure as intact and expects further growth on improved sentiment. "With major catalysts in place, I believe AstraZeneca offers a promising setup for continued upside within the GBX13,950–14,798 range."

Buyers sustain upside bias despite conflicting momentum signals

AstraZeneca trades above all key moving averages, with the last traded price at GBX14,374, comfortably above the 20-day (GBX13,743), 50-day (GBX13,717), and 200-day (GBX13,738) levels. This alignment suggests ongoing short-, medium-, and long-term bullish pressure, although the longer-term trend context remains technically bearish. Immediate resistance sits at the near-term ceiling of GBX14,686, with support layered at the near-term floor of GBX14,312. Short-term momentum is mixed, with the Moving Average Convergence Divergence (MACD) signaling buy and the Average Directional Index (ADX) pointing to seller dominance. The Relative Strength Index (RSI) and Commodity Channel Index (CCI) forecasts both lean positive, yet the Stochastic RSI issues a strong sell, revealing some oscillator divergence. Bull/Bear Power (BBP) is significantly positive, confirming buyers dominate intraday momentum and reflect an overbought condition. Today the stock has jumped GBX324 or 2.31% and opened with an upside gap of about GBX168 (1.2%). The price is now trading near session highs as intraday volatility stands at 1.36%. The tone is strong to the upside, with firm pressure toward session highs, though conflicting momentum readings suggest the move is extended.

Earlier, analysts noted that AstraZeneca’s resilience was underpinned by progress in its oncology pipeline and strategic partnerships, though they cautioned that mixed technical signals could cap upside momentum. The current setup underscores this dynamic, as continued bullish pressure is counterbalanced by oscillator divergence, making a decisive break above GBX14,686 a key level to validate a new upward trend in the coming sessions.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.